Literature DB >> 23584692

Spectral-domain optical coherence tomography imaging of drusenoid pigment epithelial detachments.

Carlos Alexandre de Amorim Garcia Filho1, Zohar Yehoshua, Giovanni Gregori, Michel E Farah, William Feuer, Philip J Rosenfeld.   

Abstract

PURPOSE: To evaluate drusenoid retinal pigment epithelial detachments (DPED) secondary to age-related macular degeneration (AMD) using spectral-domain optical coherence tomography imaging.
METHODS: In this prospective natural history study, eyes from patients with the diagnosis of nonexudative AMD and DPEDs were followed for at least 6 months. Eyes were scanned using the Cirrus spectral-domain optical coherence tomography instrument and the 200 × 200 A-scan raster pattern. A custom software was used to quantify volumetric changes in DPEDs and to detect the evolution and formation of geographic atrophy and choroidal neovascularization. Changes in DPED area and volume and development of the advanced forms of AMD were the main outcome.
RESULTS: Of the 130 patients (186 eyes) with nonadvanced AMD, 11 patients (16 eyes) presented with DPEDs during the study. Mean follow-up was 18.5 months. Most DPEDs had an area exceeding 1 disk area (14 of 16 eyes) based on color fundus images with a mean area of 4.19 mm(2) (SD = 1.35) measured by spectral-domain optical coherence tomography. The mean volume at the time the DPED was diagnosed was 0.48 mm(3) (SD = 0.28). Four different patterns of progression were observed: DPEDs remained unchanged in 8 of 16 eyes (50%), DPEDs tended to increase in volume before progressing to geographic atrophy in 5 eyes (31.25%) and choroidal neovascularization in 2 eyes (12.5%), and a DPED decreased by more than 50% without progressing to geographic atrophy or choroidal neovascularization in 1 eye (6.25%).
CONCLUSION: Spectral-domain optical coherence tomography imaging is able to detect subtle changes in the area and volume of DPEDs. Quantitative spectral-domain optical coherence tomography imaging of DPEDs is useful for identifying the natural history of disease progression and as a clinical tool for monitoring eyes with AMD in clinical trials.

Entities:  

Mesh:

Year:  2013        PMID: 23584692     DOI: 10.1097/IAE.0b013e318285cbd2

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  5 in total

1.  Semiautomated segmentation and analysis of retinal layers in three-dimensional spectral-domain optical coherence tomography images of patients with atrophic age-related macular degeneration.

Authors:  Zhihong Hu; Yue Shi; Kiran Nandanan; Srinivas R Sadda
Journal:  Neurophotonics       Date:  2017-02-06       Impact factor: 3.593

2.  The role of indocyanine green angiography imaging in further differential diagnosis of patients with nAMD who are morphologically poor responders to ranibizumab in a real-life setting.

Authors:  A Ozkaya; C Alagoz; R Garip; Z Alkin; I Perente; A T Yazici; M Taskapili
Journal:  Eye (Lond)       Date:  2016-04-15       Impact factor: 3.775

3.  Long-term outcomes of drusenoid pigment epithelium detachment in intermediate AMD treated with 577 nm subthreshold micropulse laser: a preliminary clinical study.

Authors:  Zhen Huang; Kai-Yu Deng; Yu-Meng Deng; Yan-Nian Hui; Yan-Ping Song
Journal:  Int J Ophthalmol       Date:  2022-03-18       Impact factor: 1.779

4.  Natural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17.

Authors:  Jeannette J Yu; Elvira Agrón; Traci E Clemons; Amitha Domalpally; Freekje van Asten; Tiarnan D Keenan; Catherine Cukras; Emily Y Chew
Journal:  Ophthalmology       Date:  2018-08-22       Impact factor: 12.079

5.  Validation of a Novel Automated Algorithm to Measure Drusen Volume and Area Using Swept Source Optical Coherence Tomography Angiography.

Authors:  Xiaoshuang Jiang; Mengxi Shen; Liang Wang; Luis de Sisternes; Mary K Durbin; William Feuer; Philip J Rosenfeld; Giovanni Gregori
Journal:  Transl Vis Sci Technol       Date:  2021-04-01       Impact factor: 3.283

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.